$7.41
1.46%
Nasdaq, Nov 19, 03:58 pm EST. Closed.
ISIN
US4525EP1011
Symbol
IMUX

Immunic, Inc. Stock price

$7.39
+0.40 5.72% 1M
-4.21 36.29% 6M
+2.05 38.47% YTD
+0.26 3.60% 1Y
-3.71 33.42% 3Y
-86.31 92.11% 5Y
-2,372.61 99.69% 10Y
-4,792.61 99.85% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.13 1.73%
ISIN
US4525EP1011
Symbol
IMUX
Industry

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$119.4m
Enterprise Value
$-35.7m
Net debt
positive
Cash
$155.1m
Shares outstanding
13.6m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.4 | 0.3
P/B
0.9
Financial Health
Equity Ratio
-27.7%
Return on Equity
1,456.2%
ROCE
-92.2%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$16.2m | -
SBC as % of FCF
-
SBC Growth 1Y
106.3%
Share Count Growth 1Y
38.2%
Shareholder Yield
-38.2%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-117.7m
EBIT
$-117.9m
Net Income
$-111.6m
Free Cash Flow | ex SBC
$-88.1m | $-104.2m
Growth
Revenue | estimate
- | -
EBITDA
-12.0%
EBIT
-12.0%
Net Income
-9.6%
Free Cash Flow
2.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.6
FCF per Share
$-6.5
Short interest
15.1%
Employees
92
Rev per Employee
$0.0

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Immunic, Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Immunic, Inc. forecast:

Buy
95%
Hold
5%

Immunic, Inc. Events

Past Events
NOV
13
Q3 2026 Earnings Call
6 days ago
NOV
5
Special Call - Immunic, Inc.
14 days ago
SEP
9
Special Call - Immunic, Inc.
2 months ago

Financial data from Immunic, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
41% 41%
-
- Research and Development Expense 91 91
6% 6%
-
-118 -118
12% 12%
-
- Depreciation and Amortization 0.15 0.15
6% 6%
-
EBIT (Operating Income) EBIT -118 -118
12% 12%
-
Net Profit -112 -112
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Neutral
PRNewsWire
●
7 days ago
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled Expected in the First Half of 2027 – – Executive Leadership Team Further Strengthened with App...
Neutral
PRNewsWire
●
22 days ago
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET. In addition to members of Immunic's manage...
Neutral
PRNewsWire
●
30 days ago
– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period – – New Preclinical Data Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects Beyond DHODH Inhibition – ...
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Dr. Vitt
Employees 92
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today